N-acetyl-L-cysteine for the treatment of endometriosis

it has previously been proposed that NAC could be used in new therapeutic strategies for endometriosis, based on its use as an antioxidant and a ROS scavenger. The inventors of the present disclosure show that NAC induces molecular and cellular changes that not only inhibit proliferation but also induce differentiation of the diseased tissue towards normal tissueThese findings have led the inventors of the present invention to propose a new prescription of NAC in the treatment of endometriosis and of indications associated with endometriosis, in a human or mammalian animal patient. ln addition an effective dose range of NAC in the treatment of endometriosis is proposed. In one embodiment of the present invention the prescribed treatment regimen may be used e.g in order to control the frequency and the intensity of pain symptoms (dysmenorrhea, dyspareunia and acyckic chronic pelvic pain), to reduce the size of endometriotic lesions eventually up to their disappearance, to reduce recurrences after surgery and/or to improve fertility. Side effects of this treatment are virtually absent and, in particular, this treatment does not hinder pregnancy. The present invention provides a pharmaceutical composition for the treatment of endometriosis comprising N-acetyl-L-cysteine.